COMPANY NEWS


Zydus Lifesciences Ltd
BSE Code 532321 ISIN Demat INE010B01027 Book Value (₹) 145.11 NSE Symbol ZYDUSLIFE Div & Yield % 0.61 Market Cap ( Cr.) 99,939.16 P/E * 37.18 EPS * 26.71 Face Value (₹) 1
* Profit to Earning Ratio
* Earning Per Share
Zydus Lifesciences receives USFDA approval for Isosorbide Mononitrate ER Tablets Back
(16 Feb 2024)

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Isosorbide Mononitrate Extended-Release, Tablets USP, 30 mg, 60 mg, and 120 mg (USRLD: Imdur® Extended-Release Tablets).

Isosorbide mononitrate is used to prevent chest pain (angina) in patients with a certain heart condition (coronary artery disease).

The product will be manufactured at the group's formulation manufacturing facility at Ahmedabad SEZ, India.

Isosorbide Mononitrate Extended-Release, Tablets USP, 30 mg, 60 mg, and 120 mg had annual sales of USD 47 mn in the United States (IQVIA Dec. Nov. 2023).